What?s Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR-Mutated Non-Small-Cell Lung Cancer

被引：2
作者：
Rotow, Julia K. [1 ]
Janne, Pasi A. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 02期
关键词：
PHASE-III TRIAL; BRAIN METASTASES; OPEN-LABEL; 1ST-LINE TREATMENT; GEFITINIB; ERLOTINIB; COMBINATION; CARBOPLATIN; PACLITAXEL; CISPLATIN;
D O I：
10.1200/JCO.19.02724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：107 / +
页数：5
相关论文
共 29 条
[1]  
[Anonymous], ANN ONCOL S8
[2]  
[Anonymous], 2019, ANN ONCOL
[3]   Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma [J].
Bailon, Olivier ;
Chouahnia, Kader ;
Augier, Alexandre ;
Bouillet, Thierry ;
Billot, Segolene ;
Coman, Irene ;
Ursu, Renata ;
Belin, Catherine ;
Zelek, Laurent ;
Des Guetz, Gaetan ;
Levy, Christine ;
Carpentier, Antoine F. ;
Morere, Jean-Francois .
NEURO-ONCOLOGY, 2012, 14 (04) :491-495
[4]   Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity [J].
Ballard, Peter ;
Yates, James W. T. ;
Yang, Zhenfan ;
Kim, Dong-Wan ;
Yang, James Chih-Hsin ;
Cantarini, Mireille ;
Pickup, Kathryn ;
Jordan, Angela ;
Hickey, Mike ;
Grist, Matthew ;
Box, Matthew ;
Johnstrom, Peter ;
Varnas, Katarina ;
Malmquist, Jonas ;
Thress, Kenneth S. ;
Janne, Pasi A. ;
Cross, Darren .
CLINICAL CANCER RESEARCH, 2016, 22 (20) :5130-5140
[5]   Gefitinib in patients with brain metastases from non-small-cell lung cancer:: a prospective trial [J].
Ceresoli, GL ;
Cappuzzo, F ;
Gregorc, V ;
Bartolini, S ;
Crinó, L ;
Villa, E .
ANNALS OF ONCOLOGY, 2004, 15 (07) :1042-1047
[6]   Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations [J].
Cheng, Ying ;
Murakami, Haruyasu ;
Yang, Pan-Chyr ;
He, Jianxing ;
Nakagawa, Kazuhiko ;
Kang, Jin Hyoung ;
Kim, Joo-Hang ;
Wang, Xin ;
Enatsu, Sotaro ;
Puri, Tarun ;
Orlando, Mauro ;
Yang, James Chih-Hsin .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) :3258-+
[7]   Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS) [J].
Fukuoka, Masahiro ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Sunpaweravong, Patrapim ;
Leong, Swan-Swan ;
Sriuranpong, Virote ;
Chao, Tsu-Yi ;
Nakagawa, Kazuhiko ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Duffield, Emma L. ;
Rukazenkov, Yuri ;
Speake, Georgina ;
Jiang, Haiyi ;
Armour, Alison A. ;
To, Ka-Fai ;
Yang, James Chih-Hsin ;
Mok, Tony S. K. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2866-2874
[8]   Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial [J].
Gatzemeier, Ulrich ;
Pluzanska, Anna ;
Szczesna, Aleksandra ;
Kaukel, Eckhard ;
Roubec, Jaromir ;
De Rosa, Flavio ;
Milanowski, Janusz ;
Karnicka-Mlodkowski, Hanna ;
Pesek, Milos ;
Serwatowski, Piotr ;
Ramlau, Rodryg ;
Janaskova, Terezie ;
Vansteenkiste, Johan ;
Strausz, Janos ;
Manikhas, Georgy Moiseevich ;
Von Pawel, Joachim .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1545-1552
[9]   Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].
Giaccone, G ;
Herbst, RS ;
Manegold, C ;
Scagliotti, G ;
Rosell, R ;
Miller, V ;
Natale, RB ;
Schiller, JH ;
von Pawel, J ;
Pluzanska, A ;
Gatzemeier, M ;
Grous, J ;
Ochs, JS ;
Averbuch, SD ;
Wolf, MK ;
Rennie, P ;
Fandi, A ;
Johnson, DH .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784
[10]   Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 [J].
Herbst, RS ;
Giaccone, G ;
Schiller, JH ;
Natale, RB ;
Miller, V .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :785-794
123